Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Chugai receives approval for Xeloda indication

Chugai receives approval for Xeloda indication

14th December 2007

Chugai has received approval for a new indication of postoperative adjuvant chemotherapy for colon cancer and the overseas dosage and administration for its cancer agent Xeloda 300mg.

Xeloda obtained its first regulatory approval in the US, Switzerland and Canada in 1998 and in the EU in 2001.

It was initially launched in the Japanese market as a treatment for inoperable or recurrent breast cancer in June 2003.

The oral fluoropyrimidine ‘capecitabine’ is now approved in over 100 countries worldwide and has been used by over 1.5 million patients in the treatment for metastatic breast cancer, colorectal cancer and advanced gastric cancer.

Trials have shown Xeloda to be effective for postoperative adjuvant chemotherapy for colon cancer.

Colon cancer patients treated with the cancer agent for postoperative adjuvant chemotherapy were shown to achieve a disease-free survival and an overall survival that was equivalent or improved to those achieved by patients treated with 5-FU/LV – the global standard treatment.

Earlier this month, Chugai Pharmaceutical and Roche announced the submission of a marketing authorisation application to the European Medicines Evaluation Agency for Actemra (tocilizumab) as a treatment for the signs and symptoms of rheumatoid arthritis.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.